| Name | Title | Contact Details |
|---|
About Kotak Mahindra Group: Established in 1985, the Kotak Mahindra Group is one of Indias leading financial services conglomerates. In February 2003, Kotak Mahindra Finance Ltd. (KMFL), the Groups flagship company, received a banking license from the Reserve Bank of India (RBI). With this, KMFL became the first non-banking finance company in India to become a bank – Kotak Mahindra Bank Limited. The consolidated balance sheet of Kotak Mahindra Group is over 1 lakh crore and the consolidated net worth of the Group stands at 13,943 crore (approx US$ 2.6 billion) as on September 30, 2012. The Group offers a wide range of financial services that encompass every sphere of life. From commercial banking, to stock broking, mutual funds, life insurance and investment banking, the Group caters to the diverse financial needs of individuals and the corporate sector. The Group has a wide distribution network through branches and franchisees across India, and international offices in London, New York, California, Dubai, Abu Dhabi, Bahrain, Mauritius and Singapore. For more information, please visit the companys website at http://www.kotak.com
U.S. Figure Skating is the national governing body for figure skating in the United States, established in 1921. Based in Colorado Springs, Colorado, it is recognized by the United States Olympic & Paralympic Committee and is a member of the International Skating Union. The organization promotes figure skating through various services and programs. U.S. Figure Skating offers competitive pathways for skaters, including testing and competition opportunities that lead to World and Olympic events. The "Learn to Skate USA" program supports both recreational and competitive skaters, with over 1,000 active programs across 49 states. The organization also provides resources for member clubs and offers volunteer opportunities in roles such as judging and officiating. Additionally, it sanctions competitions and provides educational materials for coaches and skaters. The organization serves a diverse customer base, including over 750 member clubs, individual skaters, and supporters of figure skating. U.S. Figure Skating is also home to the World Figure Skating Museum and Hall of Fame, attracting thousands of visitors each year.
XLI is a full service manufacturer of precision engineered mechanical components and complex electro-mechanical subassemblies for applications including motorized vehicles, firearms, security instrumentation and communications. XLI manufactures your product according to your specifications and delivery requirements on a repetitive, low volume production basis in our U. S. facilities. Our organization provides complete customer support from engineering to manufacturing to product testing, packaging and delivery to streamline your procurement effort and expense.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.